Our Platforms

Umoja is building an integrated system of cellular immunotherapy platforms that reprogram a patient’s immune system to target and attack cancer. Our next-generation immunotherapies leverage the individual and synergistic benefits of our proprietary platforms, each of which is designed to meaningfully advance the cancer immunotherapy field.


Umoja is developing an innovative approach that overcomes many of the limitations of engineered cellular immunotherapies by empowering the patient’s body to manufacture its own engineered immune cells.

Current immunotherapies have limitations due to:
  • A time-consuming, ex vivo manufacturing process with limited scalability
  • Overstimulation of the immune system that can cause unwanted side effects
  • Unpredictable efficiency due to a hostile tumor microenvironment and tumor diversity
Our integrated cellular immunotherapies will:
  • Eliminate the need for external T-cell manufacturing or a pre-conditioning process for the patient
  • Prioritize safety by creating a fully controllable immune response that can be rapidly accelerated or braked
  • Precisely attack both tumor cells and stromal elements that tumors use to hide from the body’s native anti-tumor defenses

Umoja’s three core platforms function together in a complementary way. We apply VivoVec and a RACR/CAR payload architecture to stimulate the body to grow a population of tumor fighting T cells, and then deploy TumorTags to directly and controllably attack a tumor [while minimizing adverse effects].


In Vivo Gene Delivery

  • Acts in vivo through the body’s natural immune organ, the lymphatic system, to generate a population of cancer fighting cells (or CAR T cells)  – which are genetically retooled with our RACR/CAR systems to allow your physician to control their function.
  • Eliminates the complexity, delay, and expense required for external manufacturing of cellular therapies.


In Vivo Cell Programming

  • CAR T cells generated by the body as a result of VivoVec administration are fully controllable – their activity can be rapidly accelerated or braked by Umoja’s RACR/CAR payload architecture.
  • RACR/CAR technology can be used to enhance ex vivo manufacturing while also providing the preferential in vivo expansion signal, thus circumventing the requirement for a pre-conditioning step for the patient.
  • Control and avoiding adverse effects are intrinsic engineering principles – your doctor directs the activity of your therapeutic cells.


Universal CAR Tumor Targeting

  • Binds to cancer cells and “tags” them as targets for CAR T cells, resulting in a precise and highly potent attack on the cancer.
  • Enables combinatorial targeting of both tumor cells and stromal elements that tumors use to hide from the body’s native anti-tumor defenses.
  • TumorTag may represent one step on a path to a universal process for cancer therapy.
  • Technology can be leveraged to use a universal CAR with ex vivo (autologous or allogeneic) manufactured cells to increase targeting flexibility.
“Our approach is scalable and flexible — we aspire to create immunotherapies that are accessible and valuable for patients across the full range of solid tumors.”
— Andy Scharenberg, CEO Umoja Biopharma

Umoja is committed to developing next-generation immunotherapies that are broadly accessible for cancer patients in order to enable them to live better, fuller lives.